

Jonathan W Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4753679/publications.pdf>

Version: 2024-02-01

46
papers

3,916
citations

279487

23
h-index

288905

40
g-index

46
all docs

46
docs citations

46
times ranked

5986
citing authors

#	ARTICLE	IF	CITATIONS
1	Durvalumab plus platinum ⁺ etoposide versus platinum ⁺ etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	6.3	1,274
2	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	5.8	520
3	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
4	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	7.7	219
5	Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	3.2	149
6	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1363-1372.	0.5	140
7	A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. <i>BMC Cancer</i> , 2013, 13, 152.	1.1	99
8	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 891-902.	5.2	92
9	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	1.6	81
10	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal ⁺ epithelial) Tj ETQq0 0 0 rgBT/Overlock	2.0	74
11	Pozotinib in Non ⁺ Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 710-718.	0.8	72
12	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	1.6	70
13	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1910-1919.	3.2	66
14	A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 604-613.	1.2	65
15	High efficiency vortex trapping of circulating tumor cells. <i>Biomicrofluidics</i> , 2015, 9, 064116.	1.2	60
16	MET-Mutated NSCLC with Major Response to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, e33-e34.	0.5	53
17	Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. <i>Oncologist</i> , 2016, 21, 1326-1336.	1.9	49
18	Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non ⁺ Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2016, 17, 80-84.	1.1	45

#	ARTICLE	IF	CITATIONS
19	Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met overexpressing (OE) advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9016-9016.	0.8	33
20	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. Journal of Thoracic Oncology, 2018, 13, 1284-1293.	0.5	30
21	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clinical Cancer Research, 2021, 27, 5781-5792.	3.2	30
22	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401775163.	1.4	29
23	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52.	0.9	28
24	The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Review of Anticancer Therapy, 2021, 21, 1105-1124.	1.1	26
25	Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.. Journal of Clinical Oncology, 2022, 40, 9008-9008.	0.8	24
26	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2018, 19, e19-e28.	1.1	17
27	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clinical Cancer Research, 2022, 28, 2286-2296.	3.2	14
28	ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study. Clinical Cancer Research, 2022, 28, 2517-2526.	3.2	14
29	Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9013-9013.	0.8	14
30	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib. Clinical Lung Cancer, 2022, 23, 300-310.	1.1	12
31	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	0.8	11
32	A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 3630-3640.	3.2	11
33	Targeting MEK for the Treatment of Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, S377-S378.	0.5	10
34	nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology, 2018, 8, 262.	1.3	9
35	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clinical and Research Reports, 2022, 3, 100262.	0.6	7
36	KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. Translational Lung Cancer Research, 2019, 8, 706-709.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncology Practice, 2022, 18, e484-e494.	1.4	3
38	Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study.. Health Psychology, 2022, 41, 301-310.	1.3	3
39	Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Clinical and Translational Science, 2021, 14, 664-670.	1.5	2
40	A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.. Journal of Clinical Oncology, 2022, 40, 9038-9038.	0.8	1
41	Immunogenicity and disease control induced by a multineoantigen vaccine (ADXS-503) in patients with metastatic non-small cell lung cancer who have progressed on pembrolizumab.. Journal of Clinical Oncology, 2022, 40, 9042-9042.	0.8	1
42	Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. Journal of Thoracic Oncology, 2019, 14, 160-162.	0.5	0
43	Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).. Journal of Clinical Oncology, 2022, 40, 8582-8582.	0.8	0
44	Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.. Journal of Clinical Oncology, 2022, 40, 8571-8571.	0.8	0
45	Inter-reader reliability of immune-specific response criteria (irRECIST & iRECIST).. Journal of Clinical Oncology, 2022, 40, e21108-e21108.	0.8	0
46	Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9154-TPS9154.	0.8	0